Expert Ratings For United Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 7 analysts have shared their evaluations of United Therapeutics (NASDAQ:UTHR), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 5.05% to $310.43. Analysts from firms like JP Morgan, Goldman Sachs, and Oppenheimer have raised their price targets, reflecting positive sentiment. Despite strong revenue growth, the company faces challenges in profitability and returns.
May 21, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a generally positive sentiment towards United Therapeutics (NASDAQ:UTHR) with a 5.05% increase in the average 12-month price target to $310.43. The company has demonstrated strong revenue growth but faces challenges in profitability and returns.
The increase in the average 12-month price target and the positive sentiment from multiple analysts suggest a likely short-term positive impact on UTHR's stock price. However, challenges in profitability and returns may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100